Composite tablet capable of treating peptic ulcer and preparation method thereof

A technology for peptic ulcer and compound tablet, which is applied in the field of medicine, can solve the problems of various types, reduce the patient's oral compliance, and high oral ineffective ingredients, and achieve the effects of improving stability, reducing gastric irritation and good stability.

Inactive Publication Date: 2009-08-19
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the disadvantage of cocktail therapy is that there are many kinds of medicines taken by patients...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite tablet capable of treating peptic ulcer and preparation method thereof
  • Composite tablet capable of treating peptic ulcer and preparation method thereof
  • Composite tablet capable of treating peptic ulcer and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] One-time prescription of compound preparation

[0064] Lansoprazole 30mg

[0065] Metronidazole 300mg

[0066] Clarithromycin 500mg

[0067] Potassium Bismuth Citrate 200mg

[0068] (1) Preparation of lansoprazole cyclodextrin inclusion compound

[0069] Lansoprazole 1 part mole fraction

[0070] HP-β-CD mole fraction 1 part

[0071] NaHCO 3 Right amount

[0072] NaOH amount

[0073] Step: Configure NaHCO 3 Adjust the pH of the 0.3mol / L solution to 12 with NaOH solution, dissolve HP-β-CD in the above solution, heat and stir at 40°C, dissolve lansoprazole with an appropriate amount of 95% ethanol and add it dropwise to the heated and stirred solution. The inclusion reaction is 2 hours. After the reaction, it was freeze-dried to obtain clathrate powder.

[0074] (2) Preparation of inclusion compound antibiotic compound tablet core

[0075] The inclusion compound is equivalent to 30g of the main drug

[0076] Metronidazole 300g

[0077] Clarithromycin 500g

[0078...

Embodiment 2

[0096] One-time prescription of compound preparation

[0097] Lansoprazole 30mg

[0098] Metronidazole 300mg

[0099] Clarithromycin 500mg

[0100] Potassium Bismuth Citrate 200mg

[0101] (1) Lansoprazole self-emulsification

[0102] Lansoprazole 30g

[0103] Ethyl oleate 5g

[0104] OP 80g

[0105] PEG400 15g

[0106] Stir and mix ethyl oleate, OP and PEG400 evenly. Dissolve lansoprazole in the mixture and set aside.

[0107] (2) Preparation of inclusion compound antibiotic compound tablet core

[0108] Lansoprazole self-emulsifying, equivalent to 30g of main drug

[0109] Metronidazole 300g

[0110] Clarithromycin 500g

[0111] MCC 700g

[0112] PVP-XL 50g

[0113] Steps: The metronidazole, clarithromycin, and MCC that have passed through a 100-mesh sieve are mixed and passed through a 100-mesh sieve, and lansoprazole is self-emulsified as a binder to prepare a soft material. Pass 80 mesh sieve to make wet granules. Dry at a low temperature of 40°C, pelletize, adjust the pressu...

Embodiment 3

[0129] One-time prescription of compound preparation

[0130] Lansoprazole 30mg

[0131] Metronidazole 300mg

[0132] Clarithromycin 500mg

[0133] Potassium Bismuth Citrate 200mg

[0134] (1) Preparation of lansoprazole cyclodextrin inclusion compound

[0135] Lansoprazole 1 part mole fraction

[0136] HP-β-CD mole fraction 1 part

[0137] NaHCO 3 Right amount

[0138] NaOH amount

[0139] Configure NaHCO 3 Adjust the pH of the 0.3mol / L solution to 12 with NaOH solution, dissolve HP-β-CD in the above solution, heat and stir at 40°C, dissolve lansoprazole with an appropriate amount of 95% ethanol and add it dropwise to the heated and stirred solution. The inclusion reaction is 2 hours. After the reaction, it was freeze-dried to obtain clathrate powder.

[0140] (2) Preparation of inclusion compound antibiotic compound tablet core

[0141] Inclusion compound equivalent to 30g of main drug

[0142] Metronidazole 300g

[0143] Clarithromycin 500g

[0144] Optimized MCC 400g-1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of drugs, and relates to a compound tablet for treating peptic ulcer and a method for preparing the same. In the compound tablet, an anti acid agent (an H2 receptor blocking agent and a proton pump inhibitor) and an united synergic agent of an antibiotic or two types of antibiotics or disunited synergic agent are used as a tablet core. The tablet core comprises main materials and auxiliary materials, wherein the main materials consist of an anti acid agent, a stomach mucous membrane protective agent and one or two types of antibacterial agents; the dosage range of the anti acid agent is between 10 and 40mg, and the cyclodextrin is adopted for coating or self emulsification; the dosage range of each type of antibacterial drug is between 100 and 1,000mg; and the dosage range of the stomach mucous membrane protective agent is between 100 and 500mg. By adopting the reaction of the anti acid agent and the cyclodextrin to prepare a coating matter or for self emulsification, the anti acid agent is treated, and the treated anti acid agent, antibacterial drugs and proper amount of auxiliary materials are pressed into the tablet core, and the tablet core is externally coated with an enteric coating or pressed into the enteric coating. The compound tablet and the method have the advantages of obviously improving the stability and the bioavailability of the anti acid agent and the antibiotics, and simultaneously effectively lowering the irritation of certain antibiotics on stomach.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and relates to a compound tablet for treating peptic ulcer, especially gastric ulcer, and a preparation method thereof. Background technique [0002] Peptic ulcer mainly refers to chronic ulcers that occur in the stomach and duodenum, and is a common and frequently-occurring disease in clinical practice. Since the discovery of ulcers in the middle of the 19th century, the treatment methods mainly include antacid therapy, acid suppression therapy, antibacterial therapy and mucosal protection therapy. [0003] Nowadays, peptic ulcer is recognized as the therapy for eradication of Helicobacter pylori (HP). However, the abuse of antibiotics and HP resistance have led to a lower and lower cure rate of using antibiotics to kill HP to treat peptic ulcers. [0004] Clinically, it has been found that the cocktail therapy of antacids combined with two antibiotics and gastric mucosal protective agents can effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/28A61K45/06A61K47/48A61K47/44A61K47/34A61P1/04A61K47/10A61K47/69
Inventor 王思玲姜同英张帆
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap